Our Technology
Behind our technology
The discovery of our breakthrough monoclonal antibody technology traces back to the pioneering work of Professor Michel Cogné.
With a deep passion for immunology and years of dedicated research, Professor Cogné achieved a remarkable advancement that would transform the diagnostic field.
His innovative approach to antibody development led to the creation of our patented platform, capable of producing highly specific and reliable monoclonal antibodies.
This technology has since become the cornerstone of our company, enabling us to develop cutting-edge solutions that support more accurate and efficient diagnostic tests worldwide.
Our partners
Engineering for success
Thanks to this patented technology, we are pioneers in the design and production of human Fc monoclonal antibodies.
Our patented technology platform
With our unique patented technology platform, each mouse line hosts only one human isotype, ensuring unmatched specificity and consistency in antibody production. Coupled with fully human Fc regions, our antibodies minimize immunogenicity while maximizing functionality, setting a new standard for precision diagnostics. Moreover, our platform preserves the complete immune repertoire of the mouse, allowing for unparalleled exploration of antigen-antibody interactions. By maintaining the natural VDJ recombination and hypermutation pathway, we uphold the highest quality standards, delivering reliable and reproducible results every time.
Patents
Immunoglobulin A antibodies
Transgenic non-human mammal for producing chimeric human immunoglobulin A antibodies
Immunoglobulin G antibodies
Transgenic non-human mammal for producing chimeric human immunoglobulin G antibodies
Immunoglobulin E antibodies
Transgenic non-human mammal for producing chimeric human immunoglobulin E antibodies
Why does human Fc matter?
Traditional mAbs often incorporate a non-human Fc region, leading to potential drawbacks:
- Immunogenicity: The body may recognize the foreign Fc domain, triggering an immune response that reduces efficacy.
- Limited effector functions: Non-human Fc domains may not effectively interact with the human immune system, hindering the mAb’s ability in applications like diagnostics and therapeutics.
